Overview

Anlotinib After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer（ALTER-L029）

Status:
Recruiting
Trial end date:
2021-11-30
Target enrollment:
Participant gender:
Summary
Evaluate the efficacy and safety of Anlotinib following concurrent chemoradiation in patients with stage III unresectable non-small cell lung cancer
Phase:
Phase 2
Details
Lead Sponsor:
Anhui Shi, MD
Collaborators:
Beijing Cancer Hospital
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.